cdaniel394 and this whole board of FAULTY posters have been WRONG for the last 18 mos plus and here's the closing KABOOSH:
maverick_1 Monday, 05/15/17 07:01:55 PM Re: reg2015 post# 117583 Post #117599 of 117603 re IMUC's ICT-107; Here's what was cited in their press release: Quote: re-evaluation of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma. Despite having made meaningful progress in executing the ongoing phase 3 registration trial of ICT-107, it has become clear that ImmunoCellular's ability to access sufficient additional financial resources needed to complete the trial and continue its ongoing operations are limited. As of March 31, 2017, the Company had $5.3 million in cash. Accordingly, ImmunoCellular's board of directors has undertaken a strategic review to determine the feasibility of continuing to execute this trial independently or completing development through a partnership or acquisition of the asset. Given its limited financing options, ImmunoCellular is considering restructuring its business if a partner or acquirer for ICT-107 is not identified in the near term, but in any event, not later than 30 days. While this review is in progress, ImmunoCellular also intends to evaluate strategies to refocus and reallocate its available resources on its promising Stem-to-T-Cell research programs
https://seekingalpha.com/pr/16833459-immunocellular-therapeutics-announces-first-quarter-2017-financial-results Quote: 1. Nature of Organization (Planned Principal Operations Have Not Commenced) ImmunoCellular Therapeutics, Ltd. (the Company) is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. These condensed consolidated financial statements include the Company’s wholly owned subsidiaries, ImmunoCellular Bermuda, Ltd. in Bermuda and ImmunoCellular Therapeutics (Ireland) Limited and ImmunoCellular Therapeutics (Europe) Limited in Ireland, that were formed during 2014. The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing for its immunotherapy product candidates, and has not generated any recurring revenues. The Company has begun phase 3 testing of its lead product candidate, ICT-107, in which the Company originally anticipated randomizing 414 patients at about 120 clinical sites in the United States, Canada and Europe. The Company submitted an amendment to the phase 3 protocol to the FDA on December 30, 2016 that modifies some elements of how patients qualify for the trial, raises the target number of randomized patients to 542 , and extends completion of the trial to mid-2021. The amendment was allowed by the FDA in March 2017. The Company has submitted similar protocol amendments to regulatory agencies in Canada and the European countries participating in the trial. The Company has two other product candidates, ICT-140 and ICT-121, both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). During the third quarter of 2016, the Company completed its enrollment of ICT-121 and closed the trial in March 2017. The Company is holding the initiation of its ICT-140 trial until it can find a partner for the program to share expenses or until it has secured sufficient financial resources to complete the ICT-107 phase 3 program Additionally, the Company has acquired the rights to technology for the development of certain Stem-to-T-cell immunotherapies for the treatment of cancer. The Company has incurred operating losses and, as of March 31, 2017 , the Company had an accumulated deficit of $102,048,429 . The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated. https://seekingalpha.com/pr/16833459-immunocellular-therapeutics-announces-first-quarter-2017-financial-results
Note I've been NEGATIVE on IMUC for close to two years and it has declined substantially for all the right reasons specified in my iHub posts.
